Quadrivalent Global Market Report 2026

A quadrivalent vaccine is designed to stimulate the immune system by responding to four different antigens, typically representing four distinct viruses or bacteria. Most commonly, quadrivalent vaccines are used to protect against four types of flu viruses, with two of them being type A and two being type B.

Quadrivalent vaccines are administered in different forms, including intradermal shots, intramuscular injections, and nasal sprays. An intradermal shot involves injecting the vaccine between the epidermis (top layer of skin) and hypodermis (bottom layer of skin), as per the Centers for Disease Control and Prevention (CDC). These vaccines are produced using various technologies such as conjugated, live, inactivated, recombinant, toxoid, and others. They are used for immunization against a wide range of diseases, including cancer, hepatitis, pneumococcal disease, COVID-19, influenza, human papillomavirus (HPV), meningococcal disease, polio, rotavirus, and more, serving both pediatric and adult populations. Distribution channels for these vaccines include hospitals, pharmacies, government suppliers, and other outlets.

Tariffs have influenced the quadrivalent vaccine market by increasing the cost of imported raw materials and vaccine components, affecting production timelines and supply chain efficiency. Regions heavily reliant on imports, such as Asia-Pacific and Africa, are most impacted, while segments like intramuscular and nasal spray vaccines face higher production costs. However, tariffs may encourage local manufacturing and sourcing strategies, potentially boosting domestic production capabilities and innovation in vaccine delivery solutions.

The quadrivalent market research report is one of a series of new reports from The Business Research Company that provides quadrivalent market statistics, including quadrivalent industry global market size, regional shares, competitors with a quadrivalent market share, detailed quadrivalent market segments, market trends and opportunities, and any further data you may need to thrive in the quadrivalent industry. This quadrivalent market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The quadrivalent market size has grown strongly in recent years. It will grow from $9.51 billion in 2025 to $10.44 billion in 2026 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to growing prevalence of influenza, government vaccination initiatives, advances in vaccine research, increasing public awareness about flu prevention, early adoption of quadrivalent vaccines in developed regions.

The quadrivalent market size is expected to see rapid growth in the next few years. It will grow to $15.37 billion in 2030 at a compound annual growth rate (CAGR) of 10.1%. The growth in the forecast period can be attributed to rising demand for broader influenza protection, innovations in vaccine delivery technologies, expansion of immunization programs in emerging markets, increasing investments in biotech and precision medicine, favorable reimbursement policies and government support. Major trends in the forecast period include vaccine formulation optimization, expanded age group immunization programs, cold chain and distribution innovations, multi-strain influenza coverage, regulatory compliance and quality assurance.

The rising immunization coverage across the globe is expected to drive the growth of the quadrivalent vaccine market. Immunization coverage refers to the proportion of the population that has received specific vaccines within a given timeframe. As immunization coverage expands, there is an increased demand for vaccines, and quadrivalent vaccines, which protect against four strains, are often integrated into routine vaccination programs to address multiple diseases in one shot. For example, in July 2025, the World Health Organization (WHO) reported that global coverage for the first dose of the HPV vaccine in girls grew from 27% in 2023 to 31% in 2024. This expanding immunization coverage will support the growth of the quadrivalent vaccine market moving forward.

Major companies in the quadrivalent vaccine market are focusing on innovative vaccine delivery technologies, such as nanoparticle technology, to enhance safety and improve immune response. Nanoparticle technology mimics the virus's outer structure using virus-like particles (VLPs), which do not contain live genetic material, thereby improving safety. For instance, in March 2024, Cadila Pharmaceuticals, an India-based company, launched the advanced Quadrivalent Influenza Vaccine (aQIV), which provides protection against four distinct strains of the influenza virus, including two A strains (H1N1 and H3N2) and two B strains. This formulation increases the vaccine's efficacy by targeting a broader range of circulating influenza strains, particularly during flu seasons. It aims to reduce influenza-related morbidity and mortality and reflects ongoing efforts to improve public health outcomes.

In February 2023, Clover Biopharmaceuticals Ltd., a China-based biotechnology company, partnered with Adimmune Corporation, a Taiwan-based biopharmaceutical firm, to leverage Adimmune's experience in manufacturing and distributing vaccines to Asian populations. This partnership supports Clover's goal of becoming a leader in respiratory vaccines while enhancing synergies with ongoing COVID-19 vaccine commercialization efforts.

Major companies operating in the quadrivalent market are AstraZeneca Plc, Serum Institute of India Private Limited, Sanofi S.A., GlaxoSmithKline Plc, CSL Limited, Bharat Biotech International Limited, Hualan Biological Engineering Inc., Merck & Co. Inc., Johnson & Johnson Services Inc., Pfizer Inc., Walvax Biotechnology Co. Ltd., Chongqing Zhifei Biological Products Co. Ltd., Biological E. Limited, GSK Biologicals SA, Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences, Wuhan Institute of Biological Products Co. Ltd., Beijing Tian Tan Biological Products Co. Ltd., Shanghai Zhijiang Bio-pharm Co. Ltd., Bio Farma, Butantan Institute, Pasteur Institute of India, China National Biotec Group Co. Ltd. (CNBG)

North America was the largest region in the quadrivalent market in 2025. The regions covered in the quadrivalent market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the quadrivalent market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The quadrivalent market consists of sales of afluria quadrivalent, fluarix quadrivalent, flublok quadrivalent, fluzone quadrivalent (influenza virus vaccine), flulaval quadrivalent, flucelvax quadrivalent, menactra and menveo. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Quadrivalent Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses quadrivalent market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for quadrivalent ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The quadrivalent market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Type: Intradermal Shot; Intramuscular Injection; Nasal Spray
• 2) By Technology: Conjugated; Live; Inactivated; Recombinant; Toxoid; Other Technologies
• 3) By Disease: Cancer; Hepatitis; Pneumococcal Disease; COVID-19; Influenza; Human Papilloma Virus; Meningococcal Disease; Polio; Rotavirus; Other Diseases
• 4) By Age Group: Pediatric; Adult
• 5) By Distribution Channel: Hospital And Pharmacy; Government Suppliers; Other Channels (NGOs)
• Subsegments:
• 1) By Intradermal Shot: Standard Intradermal Injection; Needle-Free Intradermal Delivery
• 2) By Intramuscular Injection: Standard Intramuscular Injection; Adjuvanted Intramuscular Injection
• 3) By Nasal Spray: Live Attenuated Nasal Spray; Inactivated Nasal Spray
• Companies Mentioned: AstraZeneca Plc; Serum Institute of India Private Limited; Sanofi S.A.; GlaxoSmithKline Plc; CSL Limited; Bharat Biotech International Limited; Hualan Biological Engineering Inc.; Merck & Co. Inc.; Johnson & Johnson Services Inc.; Pfizer Inc.; Walvax Biotechnology Co. Ltd.; Chongqing Zhifei Biological Products Co. Ltd.; Biological E. Limited; GSK Biologicals SA; Institute of Vaccines and Biological Products Chinese Academy of Medical Sciences; Wuhan Institute of Biological Products Co. Ltd.; Beijing Tian Tan Biological Products Co. Ltd.; Shanghai Zhijiang Bio-pharm Co. Ltd.; Bio Farma; Butantan Institute; Pasteur Institute of India; China National Biotec Group Co. Ltd. (CNBG)
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.